Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Pacific Biosciences of California, Inc. (PACB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.4700+0.0500 (+1.13%)
At close: 04:00PM EDT
4.5500 +0.09 (+2.02%)
After hours: 07:57PM EDT
Advertisement
Sign in to post a message.
  • F
    FNS
    Recent developments.
    Better coordination with Invitae.
    “ • The parties anticipate that in connection with the Amended and Restated Agreement, PacBio will continue to receive feedback, input and insight from Invitae in connection with the intended development of its new sequencing systems; however, such feedback will not be contractually required and Invitae has no contractual right to participate in decisions regarding the development program for such new sequencing systems.
    • PacBio''s development plans for such new sequencing systems will be at PacBio''s discretion and pursuant to its own internal processes and programs.
    • Invitae will not be contractually obligated to reimburse PacBio for development costs under the Amended and Restated Agreement.
    • PacBio will provide Invitae with credits and discounted pricing in connection with Invitae''s anticipated purchase of currently available and in-development sequencing systems.
    • In addition, subject to certain conditions, Invitae will be entitled to most favored pricing for the Company''s Sequel IIe systems and certain in-development systems.”
  • A
    Albertus
    Another draw down. if that previous bottom doesn't hold, hate to say it but 2-3 is possible. At that point valuations will be upside down, but the issue is a lot of investors won't have capital to buy that dip. Let's see where this all shakes out
  • T
    Tambo210
    Short interest rose by nearly ~4m to 38m as of mid-May
    Nearly 19% of float is short
  • R
    RV
    https://twitter.com/genome_gov/status/1541462264934346753

    Researchers have developed a technology called long-read sequencing that helps them read longer, more difficult stretches of DNA. During the Human Genome Project, researchers could only read 500 bases at a time. Now, they can read up to 100,000!
  • T
    Tambo210
    June 28
    9:45 A.M.
    Long-Read Sequencing Technologies
    PMWC Program Image
    Stephen Turner
    Ph.D., Founder & CTO, Pacific Biosciences

    Ultima also presenting today
  • S
    Seq
    Pst...Do not tell anybody it is going up ....
    Bullish
  • C
    Christopher
    1.95 million active Traders compared to the daily average of 7 million and the stock is up 7%. this definitely tells you it's not the retail Market moving this stock. it has all the ingredients for a short squeeze with one positive message from Christian Henry we could see this stock doing AMC considering the short interest last week was 17%. now I'm going to be very quiet not to jinx anything LOL
  • A
    Albertus
    Now that is a nice bounce! Still heavily discounted.
  • R
    RV
    https://twitter.com/PacBio/status/1539665595477917698

    PacBio
    @PacBio
    The #PacBio Iso-Seq method allows scientists like Terrance to sequence full-length RNA isoforms and identify splice variants to evaluate the expression of #AAV vectors for #genetherapy.
    This allows researchers to:  

    -Have a full picture of expressed isoforms of codon-optimized rAAV therapy variants  

    -Quantify each isoform

    -Improve codon optimization computational models w/ empirical data  

    -Include as part of R&D pipeline
  • R
    RV
    PacBio Iso-Seq of cell type-specific HOTAIR lncRNA isoforms in adipose stem cells

    https://www.biorxiv.org/content/10.1101/2022.06.17.496514v1
  • R
    RV
    Macro effects: Anybody taking this seriously!

    more risk with repeat reinfections- effect on disability and deaths and on economy - if this holds true.
    No politics please- just about evidence.

    https://www.researchsquare.com/article/rs-1749502/v1
  • R
    RV
    Precision Medicine needs precise sequencing!

    several false signals from the NGS cohort analysis... indicating that they were likely artifacts of inaccurate [short-read] sequence mapping.

    https://www.pacb.com/blog/the-hifi-difference-more-precise-genomes-for-precision-medicine/
  • C
    Crash
    Summer rally underway
    Bullish
  • A
    Aaron
    Why the spike these last few days?
  • R
    RV
    #1: IMPROVE VECTOR DESIGN WITH FULL-LENGTH AAV SEQUENCING
    #2: VERIFY EXPRESSION VECTORS ARE EXPRESSING DESIRED TRANSCRIPTS
    #3: CONFIRM CRISPR-CAS9 GENE EDITING OUTCOMES
    https://www.pacb.com/gene-therapy/

    and #4: Sequencing of the receptors and the ligands for targeted LNP would be another huge need if they got into it. There is probably dozens of different polymorphisms across a single receptor.
  • R
    RV
    A pan-genome approach to decipher variants in the highly complex tandem repeat of LPA https://biorxiv.org/cgi/content/short/2022.06.08.495395v1 #bioRxiv

    Lp(a) is an important factor in Coronary Heart disease risk, and its expression is correlated with the length of the LPA gene. The KIV-2 region of LPA consists of variable tandem repeats whose number is highly variable across individuals. Little is known about the inner diversity of the KIV-2 repeats themselves
  • R
    RV
    EUA for Sequel II (e) used at Labcorp.
  • R
    RM
    Who is the new hire who received equity shares?
  • R
    RV
    O/T: Accused for pumping CRBU on this MB yesterday.

    "Short Legendyesterday
    $CRBU is another one RV pumps - that one down 80% from just last summer."

    FACTS: CRBU Best in class.

    https://twitter.com/Biotech2k1/status/1535401306189451264/photo/1
  • A
    Albertus
    I remember loading around 1. IMO this feels just like that level again. Upside target NO idea but its massive if management can execute. You have to swing around here
    Bullish
Advertisement
Advertisement